// App-Quantinova.ai

3746 : A high dose priming strategy with the novel RNAi therapeutic GS-10 elevates RISC Ago2, Ago4 and GW182 protein levels to enhance RNAi efficacy in a metastatic solid tumor model

Researchers

Presenter

  • Lucas P. Nacusi

Principal Investigators

  • Vicci L. Korman

  • Alex J. Pretti

  • Diane K. Tobolt

  • Alvaro Mendoza

  • Gretchen M. Unger

Medical Centers

  • GeneSegues Therapeutics, Chaska, MN.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Solid malignancies

Biomarkers

  • Nucleoside diphosphate kinase A

  • Casein Kinase II

  • Tenascin-C

Drug/Treatment

  • GS10

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved